Clinical Trials · NCT00859534
Phase II Solar Urticaria (SU) Pilot Study
- Phase
- Phase 2
- Recruitment status
- Completed
- Sponsor
- Clinuvel Pharmaceuticals Limited
- Enrollment
- 5
- Start date
- Dec 2008
- Locations
- 1 site, United Kingdom
- Primary endpoint
- To determine whether a CUV1647 (synthetic alpha-MSH analogue) bioresorbable implant can reduce the susceptibility of patients with Solar Urticaria to provocation with a standardized light source (measured as a change in minimum urticarial dose, (MUD)).